Elsevier

Autoimmunity Reviews

Volume 4, Issue 1, January 2005, Pages 66-78
Autoimmunity Reviews

A meeting review
1st International Conference on Cutaneous Lupus Erythematosus Düsseldorf, Germany, September 1–5, 2004

https://doi.org/10.1016/j.autrev.2004.09.005Get rights and content

Section snippets

The pathogenesis of lupus erythematosus: what we know

David A. Norris (Denver, USA) summarized recent data on the pathogenesis of cutaneous lupus erythematosus (CLE) and addressed the questions: where are we now and where are we going? In the past decades, extensive investigations have been performed in the field of photoimmunology, and it has become evident that ultraviolet radiation (UVR) exposure can significantly compromise the immune system. The implications of the immunosuppressive properties of UVR are manifold, because UV-induced

Evaluation of patients with lupus erythematosus

Stefano Bombardieri (Pisa, Italy) reviewed the most popular indices used to measure disease activity in SLE including British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Lupus Activity Index (LAI), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). After a brief summary of the main characteristics of each one of them, he underlined as in the majority of the studies, all indices are highly

Key clinical issues

Victoria Werth (Pennsylvania, USA) started the morning session with her lecture on the clinical manifestations of CLE. She presented epidemiological data about the prevalence of the cutaneous variants of LE, which have been reported to be two- to threefold more prevalent than SLE. Moreover, the cutaneous manifestations represent the second most frequent clinical manifestation of SLE. She further illustrated the classification of the cutaneous manifestations of LE into “specific” and

Key diagnostic issues

Hiroaki Ueki (Kurashiki, Japan) referred to the Koebner phenomenon in LE. The isomorphic response of Koebner can be observed not only in psoriasis but also in various diseases, such as lichen planus, vitiligo, keloid, and also in some systemic diseases, including LE, systemic sclerosis, dermatomyositis, vasculitis, or sarcoidosis. In various subtypes of LE, the Koebner phenomenon can be seen in apparently normal skin of patients following trauma, scratching, operation scars, contact dermatitis,

Key management issues

Annegret Kuhn (Düsseldorf, Germany) reviewed the treatment of CLE. In general, management of skin lesions in patients with CLE involves combinations of local measures and systemic agents; however, before treating skin lesions in patients with CLE, it is always essential to evaluate them for signs of systemic disease. Furthermore, it is very important to provide instructions concerning methods of protection from sunlight and artificial sources of UVR, as well as avoidance of potentially

Lupus erythematosus and autoimmunity

Tetsuo Shiohara (Tokyo, Japan) reported about the immunological basis of the lichenoid tissues reaction/interface dermatitis. The lichenoid tissues reaction (LTR) is characterized by epidermal basal cell damage that is intimately associated with a massive infiltration of T cells in the upper dermis. It is present in lymphoid cell-rich diseases, such as lichen planus and erythema multiforme, as well as in various lymphoid cell-poor diseases, such as graft-vs-host disease, dermatomyositis, and

First page preview

First page preview
Click to open first page preview

References (0)

Cited by (13)

  • Development of a Core Set Questionnaire by the European Society of Cutaneous Lupus Erythematosus (EUSCLE)

    2009, Autoimmunity Reviews
    Citation Excerpt :

    In order to provide a better basis for data collection, a study group of the European Society of Cutaneous Lupus Erythematosus (EUSCLE) defined a core set of variables for the evaluation of patients with CLE, resulting in the EUSCLE Core Set Questionnaire presented here. The non-profit working group EUSCLE was initiated at the 1st International Conference on Cutaneous Lupus Erythematosus in September 2004, in cooperation with colleagues from many European countries, with the aim of forwarding the understanding and the research of CLE [9]. In addition to the collection of epidemiological data, the primary task of EUSCLE is to achieve consensus concerning evidence-based clinical standards for disease assessment and to develop diagnostic and therapeutic guidelines.

  • Mycophenolate mofetil: What is its place in the treatment of autoimmune rheumatic diseases?

    2007, Autoimmunity Reviews
    Citation Excerpt :

    Up to now, only three cases of severe thrombocytopenia and five cases of hemolytic anemia (HA) [12] related to SLE successfully treated with MMF have been reported suggesting that MMF may be an effective option in the treatment of SLE-related severe haematological manifestations [11]. Cutaneous lupus manifestations (CLE), including chronic CLE (CCLE), subacute CLE (SCLE), and acute CLE, are frequently observed in the course of SLE [13,14]. However few studies on the use of MMF in the treatment of refractory CLE are available [11], and their results are controversial.

View all citing articles on Scopus
View full text